MarketCap
Facebook
X
Telegram
Tenax Therapeutics Deferred Revenue | TENX
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 125 K | 185 K | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 K | 125 K | 155 K |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Exicure
XCUR
|
17.3 M | $ 1.09 | 3.81 % | $ 6.86 M |  USA |
 |
Cellectis S.A.
CLLS
|
452 K | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
13.5 M | $ 12.03 | 1.78 % | $ 3.59 B |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
2.4 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
1.37 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
207 K | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
170 K | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
13.2 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
7.63 M | $ 21.65 | -3.5 % | $ 1.24 B |  Niderland |
 |
Stoke Therapeutics
STOK
|
11.9 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
30.3 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
12.5 M | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
19.5 M | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
23.5 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
238 M | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Catalyst Biosciences
CBIO
|
14 K | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
24.5 K | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
6.22 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
119 K | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
17.8 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
728 K | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
248 K | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Foghorn Therapeutics
FHTX
|
43.2 M | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
12.8 B | $ 13.76 | 4.13 % | $ 11.5 B |  India |
 |
Arcturus Therapeutics Holdings
ARCT
|
8.25 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Geron Corporation
GERN
|
35 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
20 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
313 K | - | -3.76 % | $ 3.47 M | USA |
 |
Heron Therapeutics
HRTX
|
2.76 M | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Achieve Life Sciences
ACHV
|
5.04 M | $ 6.55 | 0.85 % | $ 286 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
3.72 M | $ 17.02 | 0.98 % | $ 2.29 B | Canada |
 |
iBio
IBIO
|
1.15 M | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
24.1 K | $ 10.21 | -0.37 % | $ 92.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
1.24 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Inhibikase Therapeutics
IKT
|
2.33 K | $ 1.51 | -5.03 % | $ 148 M | USA |
 |
Immunome
IMNM
|
6.94 M | $ 17.89 | -0.54 % | $ 1.56 B | USA |
|
TFF Pharmaceuticals
TFFP
|
101 K | - | -60.05 % | $ 125 K | USA |
 |
Inovio Pharmaceuticals
INO
|
46.6 K | $ 0.88 | -1.82 % | $ 41.3 M | USA |
 |
Innoviva
INVA
|
4.27 M | $ 21.06 | 1.91 % | $ 1.42 B | USA |